Does granulocyte transfusion help pediatric cancer patients with sepsis?

Sepsis‐related mortality continues to be a major concern while treating pediatric cancer patients, more so with the rise in the incidence of multidrug‐resistant organisms (MDRO). In this retrospective study conducted between January 2021 and December 2022 at a tertiary cancer center in India, granul...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2023-09, Vol.70 (9), p.e30547-n/a
Main Authors: Keerthivasagam, Swaminathan, Srinivasan, Shyam, Navkudkar, Anisha, Chichra, Akanksha, Moulik, Nirmalya Roy, Dhamne, Chetan, Narula, Gaurav, Desai, Priti, Chinnaswamy, Girish, Banavali, Shripad
Format: Article
Language:English
Subjects:
Blood culture
Cancer
Chemotherapy
febrile neutropenia
granulocyte transfusion
Hematology
Leukocytes (granulocytic)
Malignancy
Mortality
Oncology
Patients
pediatric cancer
Pediatrics
Sepsis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sepsis‐related mortality continues to be a major concern while treating pediatric cancer patients, more so with the rise in the incidence of multidrug‐resistant organisms (MDRO). In this retrospective study conducted between January 2021 and December 2022 at a tertiary cancer center in India, granulocyte transfusion was offered in addition to standard antimicrobial therapy to 64 children with hematolymphoid malignancy who developed 75 episodes of severe sepsis following intensive chemotherapy. Forty‐four (83%) of 53 blood culture proven sepsis was caused by MDROs. Thirty‐seven (70%) patients with blood culture proven sepsis cleared the organism after granulocyte transfusion. Thirty‐day mortality was 25% for the entire study cohort and 32% for patients with MDRO sepsis.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.30547